A carregar...
A phase I trial of dasatinib, a Src-family kinase Inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
PURPOSE: We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in advanced and recurrent epithelial ovarian cancer. EXPERIMENTAL DESIGN: The primary objective was to determine the maximum tolerated dose (MTD). Secondar...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3463759/ https://ncbi.nlm.nih.gov/pubmed/22837181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0507 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|